Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

This study has been completed.
Progen Pharmaceuticals
Information provided by (Responsible Party):
Medigen Biotechnology Corporation Identifier:
First received: February 7, 2005
Last updated: August 30, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2007
  Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)